➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Mallinckrodt
McKesson
Baxter
Dow

Last Updated: March 4, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Rebeccamycin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Rebeccamycin?

Rebeccamycin is an investigational drug.

There have been 12 clinical trials for Rebeccamycin. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 1999.

The most common disease conditions in clinical trials are Lymphoma, Neuroblastoma, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Case Comprehensive Cancer Center, and Barbara Ann Karmanos Cancer Institute.

Recent Clinical Trials for Rebeccamycin
TitleSponsorPhase
Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid TumorsNational Cancer Institute (NCI)Phase 1
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaNational Cancer Institute (NCI)Phase 1
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line ChemotherapyNational Cancer Institute (NCI)Phase 2

See all Rebeccamycin clinical trials

Clinical Trial Summary for Rebeccamycin

Top disease conditions for Rebeccamycin
Top clinical trial sponsors for Rebeccamycin

See all Rebeccamycin clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Mallinckrodt
McKesson
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.